Adherium Gets 510(k) Clearance for Hailie Sensor for Asthma and COPD

September 13, 2021

Melbourne, Australia-based Adherium has received the FDA’s 510(k) clearance to market its Hailie Sensor for monitoring medication use in patients with asthma or chronic obstructive pulmonary disease (COPD).

The latest version of the sensor, which is attached to the patient’s medication inhaler, is designed for use with AstraZeneca’s Symbicort (budesonide/formoterol) aerosol inhaler, to enable physicians or healthcare providers to monitor the patient’s use of the medication.

Other Hailie Sensors will follow in the coming year, providing physiological measures that include inhalation duration, volume and peak inhalation flow for 18 medications, the company said.

View today's stories